NCT01532687 - Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 13, 2012

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions

Adult Alveolar Soft Part SarcomaAdult AngiosarcomaAdult Desmoplastic Small Round Cell TumorAdult Epithelioid HemangioendotheliomaAdult Epithelioid SarcomaAdult Extraskeletal Myxoid ChondrosarcomaAdult Extraskeletal OsteosarcomaAdult FibrosarcomaAdult LeiomyosarcomaAdult LiposarcomaAdult Malignant Peripheral Nerve Sheath TumorAdult RhabdomyosarcomaAdult Synovial SarcomaAdult Undifferentiated Pleomorphic SarcomaMalignant Adult HemangiopericytomaRecurrent Adult Soft Tissue SarcomaSarcomaStage III Adult Soft Tissue Sarcoma AJCC v7Stage IV Adult Soft Tissue Sarcoma AJCC v7

Interventions

DRUG

Gemcitabine

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pazopanib

Given PO

DRUG

Pazopanib Hydrochloride

Given PO

OTHER

Placebo Administration

Given PO

Trial Locations (2)

97239

OHSU Knight Cancer Institute, Portland

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle